XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its second quarter financial results on August 6, 2013 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.
To access the conference call via the Internet, go to
. Please join the call at least 15 minutes prior to the start to ensure time for any software downloads that may be required.
To access the live conference call via phone, dial 888-275-3514. International callers may access the live call by dialing 706-679-1417. The reference number to enter the call is 25662889.
The replay of the conference call may be accessed that same day after 8:00 p.m. Eastern Time, via the Internet, at
, or via phone at 855-859-2056 for domestic callers, or 404-537-3406 for international callers. The reference number to enter the replay of the call is 25662889.
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant
(gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite
(gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with relapsing-remitting multiple sclerosis, psoriasis, spasticity related to spinal cord injury and Parkinson's disease.
are registered trademarks of XenoPort, Inc.